Half-year report · Q2

Period2024-10-01 → 2025-03-31
Filed2025-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥17.8bn2024-10-01 → 2025-03-31Cons.Net sales
Revenue¥32.2bn2023-10-01 → 2024-09-30Cons.Net sales (5-year summary)
Revenue¥16.6bn2023-10-01 → 2024-03-31Cons.Net sales
Operating income¥325m2024-10-01 → 2025-03-31Cons.Operating income
Operating income¥276m2023-10-01 → 2024-03-31Cons.Operating income
Ordinary income¥355m2024-10-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥408m2023-10-01 → 2024-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥302m2023-10-01 → 2024-03-31Cons.Ordinary income
Profit before tax¥400m2024-10-01 → 2025-03-31Cons.Income before income taxes
Profit before tax¥314m2023-10-01 → 2024-03-31Cons.Income before income taxes
Net income (owners)¥269m2024-10-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥237m2023-10-01 → 2024-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥211m2023-10-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income¥273m2024-10-01 → 2025-03-31Cons.Profit loss
Net income¥213m2023-10-01 → 2024-03-31Cons.Profit loss
Total assets¥18.5bnat 2025-03-31Cons.Assets
Total assets¥17.2bnat 2024-09-30Cons.Assets
Total assets¥19.8bnat 2024-03-31Cons.Total assets (5-year summary)
Total liabilities¥10.8bnat 2025-03-31Cons.Liabilities
Total liabilities¥9.7bnat 2024-09-30Cons.Liabilities
Net assets / equity¥7.7bnat 2025-03-31Cons.Net assets
Net assets / equity¥7.5bnat 2024-09-30Cons.Net assets
Net assets / equity¥7.6bnat 2024-03-31Cons.Net assets (5-year summary)
Cash and deposits¥1.5bnat 2025-03-31Cons.Cash and deposits
Cash and deposits¥764mat 2024-09-30Cons.Cash and deposits
Cash & equivalents¥1.5bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.2bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2023-09-30dCons.Cash and cash equivalents
Operating cash flow¥674m2024-10-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.0bn2023-10-01 → 2024-09-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥226m2023-10-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Investing cash flow¥62m2024-10-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥108m2023-10-01 → 2024-09-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥54m2023-10-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Financing cash flow¥6m2024-10-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥210m2023-10-01 → 2024-09-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥83m2023-10-01 → 2024-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥298.42024-10-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥263.542023-10-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥233.862023-10-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio40.9%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio43.0%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥1.5bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥1.5bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥9.1bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥9.1bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥7.2bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥7.2bn
—segment totalrevenue2024-10-01 → 2025-03-31¥17.8bn
—segment totalrevenue external2024-10-01 → 2025-03-31¥17.8bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥1.2bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥1.2bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥8.3bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥8.3bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥7.1bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥7.1bn
—segment totalrevenue2023-10-01 → 2024-03-31¥16.6bn
—segment totalrevenue external2023-10-01 → 2024-03-31¥16.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 508
ItemContextValueUnit
Profit loss attributable to owners of parentPrior1YTDDuration210714000JPY
Profit loss attributable to owners of parentCurrentYTDDuration268852000JPY
Profit lossPrior1YTDDuration212565000JPY
Profit lossCurrentYTDDuration272580000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration239849000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-30731000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration308000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-1073000JPY
Other comprehensive incomePrior1YTDDuration240158000JPY
Other comprehensive incomeCurrentYTDDuration-31805000JPY
Comprehensive incomePrior1YTDDuration452724000JPY
Comprehensive incomeCurrentYTDDuration240775000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration450903000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration236905000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration1820000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration3870000JPY
Income before income taxesPrior1YTDDuration313685000JPY
Income before income taxesCurrentYTDDuration400325000JPY
Depreciation and amortization ope cfPrior1YTDDuration84036000JPY
Depreciation and amortization ope cfCurrentYTDDuration83401000JPY
Loss gain on sales of investment securities ope cfPrior1YTDDuration-14904000JPY
Loss gain on sales of investment securities ope cfCurrentYTDDuration-JPY
Increase decrease in provision ope cfPrior1YTDDuration-32429000JPY
Increase decrease in provision ope cfCurrentYTDDuration2394000JPY
Interest and dividends income ope cfPrior1YTDDuration-21650000JPY
Interest and dividends income ope cfCurrentYTDDuration-26615000JPY
Interest expenses ope cfPrior1YTDDuration1168000JPY
Interest expenses ope cfCurrentYTDDuration2002000JPY
Loss gain on sales and retirement of noncurrent assets ope cfPrior1YTDDuration3203000JPY
Loss gain on sales and retirement of noncurrent assets ope cfCurrentYTDDuration-45358000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration19957000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration-376107000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-200628000JPY
Decrease increase in inventories ope cfCurrentYTDDuration-317599000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration142113000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration914668000JPY
Other net ope cfPrior1YTDDuration3118000JPY
Other net ope cfCurrentYTDDuration44737000JPY
Subtotal ope cfPrior1YTDDuration297669000JPY
Subtotal ope cfCurrentYTDDuration681847000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration21656000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration26634000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-1168000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-2002000JPY
Income taxes paid ope cfPrior1YTDDuration-91860000JPY
Income taxes paid ope cfCurrentYTDDuration-32290000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration226297000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration674188000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-42803000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-5470000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-09-30pass rounding
balance sheet identityconsolidated 2025-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-10-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-10-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-10-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-10-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-10-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass